A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score
Abstract Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.493 |
| _version_ | 1797231389210312704 |
|---|---|
| author | Xinlong Zheng Tao Lu Shiwen Wu Xiaoyan Lin Jing Bai Xiaohui Chen Qian Miao Jianqun Yan Kan Jiang Longfeng Zhang Xiaobing Zheng Haibo Wang Yiquan Xu Weijin Xiao Cao Li Wenying Peng Jianming Ding Qiaofeng Zhong Zihua Zou Shanshan Yang Yujing Li Sihui Chen Qiuyu Zhang Jianfeng Yan Guofeng Tang Yuandong Cai Miao kang Tony S. K. Mok Gen Lin |
| author_facet | Xinlong Zheng Tao Lu Shiwen Wu Xiaoyan Lin Jing Bai Xiaohui Chen Qian Miao Jianqun Yan Kan Jiang Longfeng Zhang Xiaobing Zheng Haibo Wang Yiquan Xu Weijin Xiao Cao Li Wenying Peng Jianming Ding Qiaofeng Zhong Zihua Zou Shanshan Yang Yujing Li Sihui Chen Qiuyu Zhang Jianfeng Yan Guofeng Tang Yuandong Cai Miao kang Tony S. K. Mok Gen Lin |
| author_sort | Xinlong Zheng |
| collection | DOAJ |
| description | Abstract Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not fully encompass this heterogeneity. To better represent these nuances, we introduce the intertumoral heterogeneity response score (THRscore), a measure built upon and expanding the RECIST criteria. This retrospective study included patients with 3–10 measurable advanced lung adenocarcinoma lesions who underwent first‐line chemotherapy or targeted therapy. The THRscore, derived from the coefficient of variation in size for each measurable tumor before and 4–6 weeks posttreatment, unveiled a correlation with patient outcomes. Specifically, a high THRscore was associated with shorter progression‐free survival, lower tumor response rate, and a higher tumor mutation burden. These associations were further validated in an external cohort, confirming THRscore's effectiveness in stratifying patients based on progression risk and treatment response, and enhancing the utility of RECIST in capturing complex tumor behaviors in lung adenocarcinoma. These findings affirm the promise of THRscore as an enhanced tool for tumor response assessment in advanced lung adenocarcinoma, extending the RECIST criteria's utility. |
| first_indexed | 2024-04-24T15:43:36Z |
| format | Article |
| id | doaj.art-3aa34bb139a949b891520d29c893dd5c |
| institution | Directory Open Access Journal |
| issn | 2688-2663 |
| language | English |
| last_indexed | 2024-04-24T15:43:36Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj.art-3aa34bb139a949b891520d29c893dd5c2024-04-01T16:35:36ZengWileyMedComm2688-26632024-03-0153n/an/a10.1002/mco2.493A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response scoreXinlong Zheng0Tao Lu1Shiwen Wu2Xiaoyan Lin3Jing Bai4Xiaohui Chen5Qian Miao6Jianqun Yan7Kan Jiang8Longfeng Zhang9Xiaobing Zheng10Haibo Wang11Yiquan Xu12Weijin Xiao13Cao Li14Wenying Peng15Jianming Ding16Qiaofeng Zhong17Zihua Zou18Shanshan Yang19Yujing Li20Sihui Chen21Qiuyu Zhang22Jianfeng Yan23Guofeng Tang24Yuandong Cai25Miao kang26Tony S. K. Mok27Gen Lin28Department of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of RadiologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of OncologyFujian Medical University Union HospitalFuzhouChinaDepartment of ResearchGeneplus‐Beijing InstituteBeijing ChinaDepartment of Thoracic SurgeryClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of PathologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of PathologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaThe Second Department of OncologyYunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer CenterKunmingChinaDepartment of Radiation OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaInstitute of ImmunotherapyFujian Medical UniversityFuzhouChinaCollege of ChemistryFuzhou UniversityFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaCollege of ChemistryFuzhou UniversityFuzhouChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaDepartment of Clinical OncologyState Key Laboratory of Translational OncologyChinese University of Hong KongShatin, Hong Kong Special Administrative RegionChinaDepartment of Thoracic OncologyClinical Oncology School of Fujian Medical University, Fujian Cancer HospitalFuzhouChinaAbstract Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not fully encompass this heterogeneity. To better represent these nuances, we introduce the intertumoral heterogeneity response score (THRscore), a measure built upon and expanding the RECIST criteria. This retrospective study included patients with 3–10 measurable advanced lung adenocarcinoma lesions who underwent first‐line chemotherapy or targeted therapy. The THRscore, derived from the coefficient of variation in size for each measurable tumor before and 4–6 weeks posttreatment, unveiled a correlation with patient outcomes. Specifically, a high THRscore was associated with shorter progression‐free survival, lower tumor response rate, and a higher tumor mutation burden. These associations were further validated in an external cohort, confirming THRscore's effectiveness in stratifying patients based on progression risk and treatment response, and enhancing the utility of RECIST in capturing complex tumor behaviors in lung adenocarcinoma. These findings affirm the promise of THRscore as an enhanced tool for tumor response assessment in advanced lung adenocarcinoma, extending the RECIST criteria's utility.https://doi.org/10.1002/mco2.493intertumoral heterogeneityintertumoral heterogeneous responselung adenocarcinomaRECIST criteria |
| spellingShingle | Xinlong Zheng Tao Lu Shiwen Wu Xiaoyan Lin Jing Bai Xiaohui Chen Qian Miao Jianqun Yan Kan Jiang Longfeng Zhang Xiaobing Zheng Haibo Wang Yiquan Xu Weijin Xiao Cao Li Wenying Peng Jianming Ding Qiaofeng Zhong Zihua Zou Shanshan Yang Yujing Li Sihui Chen Qiuyu Zhang Jianfeng Yan Guofeng Tang Yuandong Cai Miao kang Tony S. K. Mok Gen Lin A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score MedComm intertumoral heterogeneity intertumoral heterogeneous response lung adenocarcinoma RECIST criteria |
| title | A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score |
| title_full | A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score |
| title_fullStr | A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score |
| title_full_unstemmed | A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score |
| title_short | A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score |
| title_sort | novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score |
| topic | intertumoral heterogeneity intertumoral heterogeneous response lung adenocarcinoma RECIST criteria |
| url | https://doi.org/10.1002/mco2.493 |
| work_keys_str_mv | AT xinlongzheng anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT taolu anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT shiwenwu anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT xiaoyanlin anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT jingbai anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT xiaohuichen anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT qianmiao anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT jianqunyan anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT kanjiang anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT longfengzhang anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT xiaobingzheng anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT haibowang anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT yiquanxu anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT weijinxiao anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT caoli anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT wenyingpeng anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT jianmingding anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT qiaofengzhong anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT zihuazou anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT shanshanyang anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT yujingli anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT sihuichen anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT qiuyuzhang anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT jianfengyan anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT guofengtang anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT yuandongcai anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT miaokang anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT tonyskmok anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT genlin anovelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT xinlongzheng novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT taolu novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT shiwenwu novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT xiaoyanlin novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT jingbai novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT xiaohuichen novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT qianmiao novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT jianqunyan novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT kanjiang novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT longfengzhang novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT xiaobingzheng novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT haibowang novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT yiquanxu novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT weijinxiao novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT caoli novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT wenyingpeng novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT jianmingding novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT qiaofengzhong novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT zihuazou novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT shanshanyang novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT yujingli novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT sihuichen novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT qiuyuzhang novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT jianfengyan novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT guofengtang novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT yuandongcai novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT miaokang novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT tonyskmok novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore AT genlin novelapproachtoevaluationoftumorresponseforadvancedpulmonaryadenocarcinomausingtheintertumoralheterogeneityresponsescore |